Poly(ADP-Ribose) Polymerase Inhibitors
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference57 articles.
1. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.;Fong;N Engl J Med,2009
2. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.;Kummar;J Clin Oncol,2009
3. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.;Plummer;Clin Cancer Res,2008
4. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.;Seimiya;Cancer Cell,2005
5. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases.;Hassa;Front Biosci,2008
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Olaparib-induced Apoptosis Through EBNA1-ATR-p38 MAPK Signaling Pathway in Epstein-Barr Virus-positive Gastric Cancer Cells;Anticancer Research;2021-12-29
2. Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target;Cancers;2021-07-09
3. Practical consensus recommendation on when to do BRCA testing;South Asian Journal of Cancer;2018-04
4. Prospects and progress of immunotherapy for bladder cancer;Expert Opinion on Biological Therapy;2017-08-23
5. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors;Clinical Cancer Research;2016-02-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3